Adverse event | Outcome | N (%) | Treatment Phase |
---|---|---|---|
Pulmonary Embolism | Death | 1 (2.5%) | Intravenous |
>33% ↑ creatinine | Dose maintained | 7 (17%) | Oral |
2 × creatinine | Dose reduced | 1 (2.5%) | Oral |
Biliary sludge | Drug discontinued | 2 (5%) | Intravenous |
↑ liver function tests | Dose maintained | 2 (5%) | Intravenous |
Seizures | Dose maintained | 1 (2.5%) | Oral |